DrugPatentWatch Database Preview
Intercept Pharms Inc Company Profile
What is the competitive landscape for INTERCEPT PHARMS INC, and when can generic versions of INTERCEPT PHARMS INC drugs launch?
INTERCEPT PHARMS INC has one approved drug.
There are seven US patents protecting INTERCEPT PHARMS INC drugs.
There are eighty-seven patent family members on INTERCEPT PHARMS INC drugs in twenty-nine countries and nine supplementary protection certificates in eight countries.
Summary for Intercept Pharms Inc
| International Patents: | 87 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Intercept Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 8,058,267 | ➤ Sign Up | ➤ Sign Up | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 10,052,337 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | 10,047,117 | ➤ Sign Up | ➤ Sign Up | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 8,377,916 | ➤ Sign Up | ➤ Sign Up | ||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Intercept Pharms Inc | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | RX | Yes | No | 10,047,117 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Intercept Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 122016011808 | ➤ Sign Up |
| Australia | 2002308295 | ➤ Sign Up |
| Brazil | 112017023161 | ➤ Sign Up |
| Denmark | 1392714 | ➤ Sign Up |
| South Korea | 101881245 | ➤ Sign Up |
| Norway | 20034011 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Intercept Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1392714 | 23/2017 | Austria | ➤ Sign Up | PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
| 1392714 | 300877 | Netherlands | ➤ Sign Up | PRODUCT NAME: OBETICHOLZUUR; REGISTRATION NO/DATE: EU/1/16/1139 20161215 |
| 1392714 | 122017000034 | Germany | ➤ Sign Up | PRODUCT NAME: OBETICHOLSAEURE; REGISTRATION NO/DATE: EU/1/16/1139 20161212 |
| 1392714 | 2017/019 | Ireland | ➤ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REGISTRATION NO/DATE: EU/1/16/1139/001 EU/1/16/1139/002 20161212 |
| 1392714 | CR 2017 00025 | Denmark | ➤ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
| 1392714 | LUC00018 | Luxembourg | ➤ Sign Up | PRODUCT NAME: ACIDE OBETICHOLIQUE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (OCALIVA); AUTHORISATION NUMBER AND DATE: EU/1/16/1139 20161215 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
